Dequanter D, Lothaire Ph
Department of Head and Neck and Thoracic Surgery, CHU Charleroi.
B-ENT. 2008;4(2):77-80.
It is now established that head & neck squamous cell carcinomas represent a major group of tumours for which an improvement in the overall survival rate could be achieved by a multimodality approach. Surgery as salvage treatment also continues to play an important role in organ preservation strategies in advanced head and neck cancer.
Before the prospective randomised organ preservation trial conducted by the Department of Veterans Affairs Laryngeal Cancer Study Group demonstrating the benefits of induction chemotherapy, the standard of care for most advanced laryngeal/pharyngo-laryngeal carcinomas was total laryngectomy/pharyngo-laryngectomy and postoperative radiotherapy. The new approach was also supported by a similar prospective trial from the EORTC Head & Neck Cooperative Group dealing with advanced hypopharyngeal squamous cell carcinomas. Currently, advanced laryngeal/pharyngo-laryngeal carcinomas are treated with chemoradiotherapy but some patients will require a more complex salvage laryngectomy/pharyngo-laryngectomy.
In a first group of 44 patients treated with sequential chemotherapy and radiotherapy, median survival was 6.7 years. The overall 5-year survival rate was 52.2%. Disease-free survival at 5 years was 50%. 20/44 (50%) of patients retained their larynx. Only 5 patients needed complex salvage surgery. In the second group of 19 patients who received concomitant chemoradiotherapy, 78.9% of the patients retained their larynx. Salvage surgery was performed in five patients.
CTx and RT is an effective strategy for organ preservation without compromising the survival of patients with locally advanced pharyngo-laryngeal carcinoma, keeping surgery for salvage.
现已确定,头颈鳞状细胞癌是一类主要的肿瘤,通过多模态方法有可能提高其总体生存率。手术作为挽救性治疗在晚期头颈癌的器官保留策略中也继续发挥着重要作用。
在退伍军人事务部喉癌研究组进行的前瞻性随机器官保留试验证明诱导化疗的益处之前,大多数晚期喉癌/喉咽癌的标准治疗方法是全喉切除术/喉咽切除术及术后放疗。欧洲癌症研究与治疗组织头颈合作组针对晚期下咽鳞状细胞癌进行的一项类似前瞻性试验也支持了这种新方法。目前,晚期喉癌/喉咽癌采用放化疗进行治疗,但一些患者将需要更复杂的挽救性喉切除术/喉咽切除术。
在第一组44例接受序贯化疗和放疗的患者中,中位生存期为6.7年。总体5年生存率为52.2%。5年无病生存率为50%。44例患者中有20例(50%)保留了喉部。仅5例患者需要进行复杂的挽救性手术。在第二组19例接受同步放化疗的患者中,78.9%的患者保留了喉部。5例患者接受了挽救性手术。
化疗联合放疗是一种有效的器官保留策略,不会影响局部晚期喉咽癌患者的生存率,同时保留手术作为挽救手段。